Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 4 , Pages 539-550 , August 2008

Cancer as an endocrine problem

References 

  1. Thompson PA. Counterpoint: genetic risk feedback for common disease time to test the waters. Cancer Epidemiology, Biomarkers & Prevention. 2007;16(9):1727–1729
  2. Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. Journal of the National Cancer Institute. 1981;66(6):1191–1308
  3. Doll R. Epidemiological evidence of the effects of behaviour and the environment on the risk of human cancer. Recent Results in Cancer Research. 1998;154:3–21
  4. Peto J. Cancer epidemiology in the last century and the next decade. Nature. 2001;411(6835):390–395
  5. Tominaga S, Kuroishi T. An ecological study on diet/nutrition and cancer in Japan. International Journal of Cancer. 1997;(Suppl 10):2–6
  6. Michels KB, Willett WC. Breast cancer–early life matters. The New England Journal of Medicine. 2004;351(16):1679–1681
  7. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer–analyses of cohorts of twins from Sweden, Denmark, and Finland. The New England Journal of Medicine. 2000;343(2):78–85
  8. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):643–646
  9. Tryggvadottir L, Sigvaldason H, Olafsdottir GH, et al. Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920–2000. Journal of the National Cancer Institute. 2006;98(2):116–122
  10. Nkondjock A, Robidoux A, Paredes Y, et al. Diet, lifestyle and BRCA-related breast cancer risk among French-Canadians. Breast Cancer Research and Treatment. 2006;98(3):285–294
  11. Vineis P. Cancer as an evolutionary process at the cell level: an epidemiological perspective. Carcinogenesis. 2003;24(1):1–6
  12. Green DR, Evan GI. A matter of life and death. Cancer Cell. 2002;1(1):19–30
  13. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70
  14. Jonason AS, Kunala S, Price GJ, et al. Frequent clones of p53-mutated keratinocytes in normal human skin. Proceedings of the National Academy of Sciences of the United States of America. 1996;93(24):14025–14029
  15. Halpern MT, Gillespie BW, Warner KE. Patterns of absolute risk of lung cancer mortality in former smokers. Journal of the National Cancer Institute. 1993;85(6):457–464
  16. Renehan AG, Bhaskar P, Painter JE, et al. The prevalence and characteristics of colorectal neoplasia in acromegaly. The Journal of Clinical Endocrinology and Metabolism. 2000;85(9):3417–3424
  17. Delongchamps NB, Singh A, Haas GP. The role of prevalence in the diagnosis of prostate cancer. Cancer Control. 2006;13(3):158–168
  18. Sakr WA, Grignon DJ, Crissman JD, et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20–69: an autopsy study of 249 cases. In Vivo (Athens, Greece). 1994;8(3):439–443
  19. Sheldon CA, Williams RD, Fraley EE. Incidental carcinoma of the prostate: a review of the literature and critical reappraisal of classification. The Journal of Urology. 1980;124(5):626–631
  20. Yatani R, Shiraishi T, Nakakuki K, et al. Trends in frequency of latent prostate carcinoma in Japan from 1965–1979 to 1982–1986. Journal of the National Cancer Institute. 1988;80(9):683–687
  21. Yatani R, Chigusa I, Akazaki K, et al. Geographic pathology of latent prostatic carcinoma. International Journal of Cancer. 1982;29(6):611–616
  22. Watanabe M, Nakayama T, Shiraishi T, et al. Comparative studies of prostate cancer in Japan versus the United States. A review. Urologic Oncology. 2000;5(6):274–283
  23. Shiraishi T, Watanabe M, Matsuura H, et al. The frequency of latent prostatic carcinoma in young males: the Japanese experience. In Vivo (Athens, Greece). 1994;8(3):445–447
  24. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. The New England Journal of Medicine. 2004;350(22):2239–2246
  25. Gosselaar C, Roobol MJ, Schroder FH. Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant?. BJU International. 2005;95(2):231–237
  26. Carroll KK. Experimental evidence of dietary factors and hormone–dependent cancers. Cancer Research. 1975;35(11 Pt. 2):3374–3383
  27. Ganmaa D, Li XM, Wang J, et al. Incidence and mortality of testicular and prostatic cancers in relation to world dietary practices. International Journal of Cancer. 2002;98(2):262–267
  28. Michels KB, Mohllajee AP, Roset-Bahmanyar E, et al. Diet and breast cancer: a review of the prospective observational studies. Cancer. 2007;109(12 Suppl):2712–2749
  29. Alberts DS, Martínez ME, Roe DJ, et al. Lack of effect of a high–fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network. The New England Journal of Medicine. 2000;342(16):1156–1162
  30. Lanza E, Yu B, Murphy G, et al. The polyp prevention trial continued follow–up study: no effect of a low–fat, high–fiber, high–fruit, and -vegetable diet on adenoma recurrence eight years after randomization. Cancer Epidemiology, Biomarkers & Prevention. 2007;16(9):1745–1752
  31. Cole BF, Baron JA, Sandler RS, et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. The Journal of the American Medical Association. 2007;297(21):2351–2359
  32. Albanes D, Heinonen OP, Taylor PR, et al. Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. Journal of the National Cancer Institute. 1996;88(21):1560–1570
  33. Hord NG, Fenton JI. Context is everything: Mining the normal and preneoplastic microenvironment for insights into the diet and cancer risk conundrum. Molecular Nutrition & Food Research. 2007;51(1):100–106
  34. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. The New England Journal of Medicine. 2003;348(17):1625–1638
  35. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nature Reviews. Cancer. 2004;4(8):579–591
  36. Hsu IR, Kim SP, Kabir M, et al. Metabolic syndrome, hyperinsulinemia, and cancer. The American Journal of Clinical Nutrition. 2007;86(3):s867–s871
  37. Pollak M. Insulin, insulin-like growth factors, insulin resistance, and neoplasia. The American Journal of Clinical Nutrition. 2007;86(suppl):820s–822s
  38. Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–314
  39. Bensaad K, Tsuruta A, Selak MA, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell. 2006;126(1):107–120
  40. Kawauchi K, Araki K, Tobiume K, et al. p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nature Cell Biology. 2008;10(5):611–618
  41. Magnard C, Bachelier R, Vincent A, et al. BRCA1 interacts with acetyl-CoA carboxylase through its tandem of BRCT domains. Oncogene. 2002;21(44):6729–6739
  42. Brunet J, Vazquez-Martin A, Colomer R, et al. BRCA1 and acetyl-CoA carboxylase: The metabolic syndrome of breast cancer. Molecular Carcinogenesis. 2007;
  43. Holly JM, Smith CP, Dunger DB, et al. Relationship between the pubertal fall in sex hormone binding globulin and insulin-like growth factor binding protein-I. A synchronized approach to pubertal development?. Clinical Endocrinology. 1989;31(3):277–284
  44. Roddam AW, Allen NE, Appleby P, et al. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. Journal of the National Cancer Institute. 2008;100(3):170–183
  45. Stoler DL, Chen N, Basik M, et al. The onset and extent of genomic instability in sporadic colorectal tumor progression. Proceedings of the National Academy of Sciences of the United States of America. 1999;96(26):15121–15126
  46. Tomlinson I, Sasieni P, Bodmer W. How many mutations in a cancer?. The American Journal of Pathology. 2002;160(3):755–758
  47. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318(5853):1108–1113
  48. Sjoblom T. Systematic analyses of the cancer genome: lessons learned from sequencing most of the annotated human protein-coding genes. Current Opinion in Oncology. 2008;20(1):66–71
  49. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nature Medicine. 2004;10(8):789–799
  50. Bardelli A, Velculescu VE. Mutational analysis of gene families in human cancer. Current Opinion in Genetics & Development. 2005;15(1):5–12
  51. Vona-Davis L, Rose DP. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocrine-Related Cancer. 2007;14(2):189–206
  52. Garofalo C, Surmacz E. Leptin and cancer. Journal of Cellular Physiology. 2006;207(1):12–22
  53. Cascio S, Bartella V, Auriemma A, et al. Mechanism of leptin expression in breast cancer cells: role of hypoxia-inducible factor-1alpha. Oncogene. 2008;27(4):540–547
  54. Arditi JD, Venihaki M, Karalis KP, et al. Antiproliferative effect of adiponectin on MCF7 breast cancer cells: a potential hormonal link between obesity and cancer. Hormone and Metabolic Research. 2007;39(1):9–13
  55. Barb D, Neuwirth A, Mantzoros CS, et al. Adiponectin signals in prostate cancer cells through Akt to activate the mammalian target of rapamycin pathway. Endocrine-Related Cancer. 2007;14(4):995–1005
  56. Goffin V, Touraine P, Culler MD, et al. Drug insight: prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinemia?. Nature Clinical Practice. Endocrinology & Metabolism. 2006;2(10):571–581
  57. Mukhina S, Mertani HC, Guo K, et al. Phenotypic conversion of human mammary carcinoma cells by autocrine human growth hormone. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(42):15166–15171
  58. Pandey V, Perry JK, Mohankumar KM, et al. Autocrine human growth hormone stimulates oncogenicity of endometrial carcinoma cells. Endocrinology. 2008;
  59. Schally AV, Varga JL, Engel JB. Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer. Nature Clinical Practice. Endocrinology & Metabolism. 2008;4(1):33–43
  60. Schally AV. New approaches to the therapy of various tumors based on peptide analogues. Hormone and Metabolic Research. 2008;40(5):315–322
  61. Yeh AH, Jeffery PL, Duncan RP, et al. Ghrelin and a novel preproghrelin isoform are highly expressed in prostate cancer and ghrelin activates mitogen-activated protein kinase in prostate cancer. Clinical Cancer Research. 2005;11(23):8295–8303
  62. Lanfranco F, Baldi M, Cassoni P, et al. Ghrelin and prostate cancer. Vitamins and Hormones. 2008;77:301–324

PII: S1521-690X(08)00085-7

doi: 10.1016/j.beem.2008.07.007

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 4 , Pages 539-550 , August 2008

Article Tools